Safety, Costs, and Efficacy of Rapid Drug Desensitizations to Chemotherapy and Monoclonal Antibodies.

@article{Sloane2016SafetyCA,
  title={Safety, Costs, and Efficacy of Rapid Drug Desensitizations to Chemotherapy and Monoclonal Antibodies.},
  author={David Edward Sloane and Usha S Govindarajulu and Jacob Harrow-Mortelliti and William T. Barry and Florence Ida Hsu and David I Hong and Tanya M. Laidlaw and Ross I Palis and Henry J. Legere and Supinda Bunyavanich and Rebecca G. Breslow and Duane R Wesemann and Nora A. Barrett and Patrick Joseph Brennan and Hey Jin Chong and Anne Y. Liu and James M. Fernandez and Laura B. Fanning and Timothy Kyin and Katherine N Cahill and Lora G. Bankova and Ashly Lynch and Suzanne T. Berlin and Susana M. Campos and Charles S. Fuchs and Robert J. Mayer and Ursula A. Matulonis and Mariana C. Castells},
  journal={The journal of allergy and clinical immunology. In practice},
  year={2016},
  volume={4 3},
  pages={
          497-504
        }
}
BACKGROUND Rapid drug desensitization (RDD) is used to address hypersensitivity reactions to chemotherapeutics and monoclonal antibodies, allowing patients to be treated with optimal pharmacological agents. RDD protocols are tailored to each individual patient's reaction and needs, and protect against anaphylaxis, but overall risks, costs, and benefits have not been determined. OBJECTIVE We investigated the safety, efficacy, costs, and life expectancy of patients in a large population… CONTINUE READING

5 Figures & Tables

Connections & Topics

Mentioned Connections BETA
A subgroup of carboplatin allergic patients with ovarian cancer treated with RDD was analyzed for costs and life expectancy and compared with a nonallergic control group .
A subgroup of carboplatin allergic patients with ovarian cancer treated with RDD was analyzed for costs and life expectancy and compared with a nonallergic control group .
A subgroup of carboplatin allergic patients with ovarian cancer treated with RDD was analyzed for costs and life expectancy and compared with a nonallergic control group .
All Topics